143 related articles for article (PubMed ID: 5094584)
1. EXcretion and distribution of iron during chronic deferoxamine therapy.
Lukens JN; Neuman LA
Blood; 1971 Nov; 38(5):614-22. PubMed ID: 5094584
[No Abstract] [Full Text] [Related]
2. Transfusion haemosiderosis inspite of regular use of desferrioxamine: case report.
Mwanda OW; Otieno CF; Abdalla FK
East Afr Med J; 2004 Jun; 81(6):326-8. PubMed ID: 16167682
[TBL] [Abstract][Full Text] [Related]
3. Urinary iron excretion in patients with prosthetic heart valves.
Walsh JR; Brodeur MT; Ritzmann LW; Sutherland DW; Starr A
JAMA; 1966 Oct; 198(5):505-10. PubMed ID: 5953308
[No Abstract] [Full Text] [Related]
4. Iron overload in cardiac valvular disease and pure red cell aplasia: treatment with desferrioxamine.
Hehlmann R; Schmitz H; Krüger K
Int J Cardiol; 1984 Jun; 5(6):749-53. PubMed ID: 6235195
[TBL] [Abstract][Full Text] [Related]
5. Combined long-term treatment of hemosiderosis with desferioxamine and DTPA in homozygous beta-thalassemia.
Constantoulakis M; Economidou J; Karagiorga M; Katsantoni A; Gyftaki E
Ann N Y Acad Sci; 1974; 232(0):193-200. PubMed ID: 4528481
[No Abstract] [Full Text] [Related]
6. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children].
Orsini A; Raybaud C; Bernard PJ; Aquaron R; Passeron P
Mars Med; 1967; 104(4):331-7. PubMed ID: 5621537
[No Abstract] [Full Text] [Related]
7. [Sideroblastic anemias].
Löhr GW
Verh Dtsch Ges Inn Med; 1978; (84):71-8. PubMed ID: 369209
[No Abstract] [Full Text] [Related]
8. [The effect of desferrioxamine on the treatment of transfusion hemosiderosis--with special reference to the method of its administration (authors' transl)].
Fujiyama N; Nakazawa K
Rinsho Ketsueki; 1977 Dec; 18(12):1393-400. PubMed ID: 604522
[No Abstract] [Full Text] [Related]
9. Ferrioxamine excretion in iron-loaded man.
Pippard MJ; Callender ST; Finch CA
Blood; 1982 Aug; 60(2):288-94. PubMed ID: 7093519
[No Abstract] [Full Text] [Related]
10. [Therapy of hemosiderosis with deferoxamine].
Strohmeyer G; Stremmel W
Dtsch Med Wochenschr; 1984 Nov; 109(44):1669-70. PubMed ID: 6489179
[No Abstract] [Full Text] [Related]
11. Iron chelation by deferoxamine in sickle cell patients with severe transfusion-induced hemosiderosis: a randomized, double-blind study of the dose-response relationship.
Silliman CC; Peterson VM; Mellman DL; Dixon DJ; Hambidge KM; Lane PA
J Lab Clin Med; 1993 Jul; 122(1):48-54. PubMed ID: 8320490
[TBL] [Abstract][Full Text] [Related]
12. [Deferoxamine in hemosiderosis. Fecal iron excretion during continuous subcutaneous infusion].
Krüger N; Kijewski H; König R; Tillmann W; Schröter W
Dtsch Med Wochenschr; 1984 Nov; 109(44):1682-5. PubMed ID: 6489181
[TBL] [Abstract][Full Text] [Related]
13. [Aplastic anemia. Diagnosis and therapy in adults].
Gjemdal T
Tidsskr Nor Laegeforen; 1974 Feb; 94(5):302-5. PubMed ID: 4594828
[No Abstract] [Full Text] [Related]
14. Effect of desferrioxamine B. A new iron eliminating agent, on cases of secondary haemosiderosis in children.
el-Gholmy A; Khalifa AS; Rahman YA; el-Bagoury I
J Trop Med Hyg; 1969 Jan; 72(1):22-6. PubMed ID: 5773810
[No Abstract] [Full Text] [Related]
15. Iron chelating therapy in thalassemia: current problems.
Russo G
Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385
[No Abstract] [Full Text] [Related]
16. [A case of Diamond-Blackfan anemia: Experiences of 10-year follow-up study].
Vadász G
MMW Munch Med Wochenschr; 1974 Nov; 116(47):2077-80. PubMed ID: 4216814
[No Abstract] [Full Text] [Related]
17. Effect of phenylhydrazine-induced haemolysis on the urinary excretion of iron after desferrioxamine.
Cumming RL; Goldberg A; Morrow J; Smith JA
Lancet; 1967 Jan; 1(7481):71-4. PubMed ID: 4163055
[No Abstract] [Full Text] [Related]
18. Effect of subcutaneous deferoxamine and oral vitamin C on iron excretion in congenital hypoplastic anemia and refractory anemia associated with the 5q-syndrome.
Ambruso DR; Mahony BS; Githens JH; Rhoades ED
Am J Pediatr Hematol Oncol; 1982; 4(2):115-23. PubMed ID: 7114394
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy of deferoxamine iron chelation therapy in adults with acquired transfusional iron overload.
Schafer AI; Rabinowe S; Le Boff MS; Bridges K; Cheron RG; Dluhy R
Arch Intern Med; 1985 Jul; 145(7):1217-21. PubMed ID: 3925909
[TBL] [Abstract][Full Text] [Related]
20. Effective combination therapy of deferiprone and deferoxamine for the rapid clearance of excess cardiac IRON and the prevention of heart disease in thalassemia. The Protocol of the International Committee on Oral Chelators.
Kolnagou A; Kontoghiorghes GJ
Hemoglobin; 2006; 30(2):239-49. PubMed ID: 16798649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
